Business
GenSight Biologics Reports Cash Position and Revenue from Early Access Program as of March 31, 2026
PARIS, April 07, 2026--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position and the revenues from its Named Patient Early Access Program as of March 31, 2026.
About this update from Gensight Biologics Sa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":204,"url":"https://media.zenfs.com/en/business-wire.com/3900b2ae8e96bb15b93334e3e4791461"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/MoSNREtmqQiNS4YAetBtdg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQwOA--/https://media.zenfs.com/en/business-wire.com/3900b2ae8e96bb15b93334e3e4791461","width":480,"height":204}},"lazy":false},{"type":"text","content":"PARIS, April 07, 2026--(BUSINESS WIRE)--Regulatory News:","length":56,"tagName":"p"},{"type":"text","content":"GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position and the revenues from its Named Patient Early Access Program as of March 31, 2026.","length":356,"tagName":"p"},{"type":"text","content":"Cash position as of March 31, 2026","length":34,"tagName":"p"},{"type":"text","content":"GenSight Biologics’ cash and cash equivalents totaled €3.2 million as of March 31, 2026, compared to €2.4 million as of December 31, 2025.","length":138,"tagName":"p"},{"type":"text","content":"The operating cash burn in the first quarter of 2026 mainly reflects the preparation and management of GS010 Early Access Programs, primarily in France, as well as the preparation of the Phase III RECOVER study for GS010/LUMEVOQ®, GenSight’s gene therapy for Leber Hereditary Optic Neuropathy (LHON).1","length":301,"tagName":"p"},{"type":"text","content":"On March 10, 2026, the Company raised nearly €1.7 million in the form of shares and warrants, including pre-funded warrants. The purpose of this fundraising was to provide the Company with a cash buffer to absorb any delays in payments from the French hospital system.","length":268,"tagName":"p"},{"type":"text","content":"Proceeds from Early Access Program","length":34,"tagName":"p"},{"type":"text","content":"Following the authorization in March of the first named patient requests in France, an initial group of patients in the GS010 Named Patient Program (AAC) were treated at the 15-20 National Hospital in Paris in later in the same month.","length":234,"tagName":"p"},{"type":"text","content":"The fi...